Genomic Analysis for Pancreatic Cancer
(PanGen Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to improve understanding and treatment of pancreatic cancer by examining genetic changes in both patients and their tumors. Researchers hope that studying these genetic differences will reveal which treatments might work best for each person after initial chemotherapy. Participants will either undergo a biopsy (a small tissue sample taken for study) or provide previous tumor samples for analysis. The trial seeks individuals with advanced pancreatic cancer who are about to start first-line chemotherapy. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to potentially groundbreaking advancements in pancreatic cancer treatment.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are currently receiving anti-cancer therapy, you would not be eligible to participate.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to redefine how we understand and treat metastatic pancreatic ductal adenocarcinoma (PDAC) by analyzing the genetic makeup of tumors. Unlike traditional treatments that often take a one-size-fits-all approach, this trial is exploring personalized treatment strategies based on the unique genomic profiles of patients' tumors. By doing so, the hope is to identify specific subtypes of PDAC, allowing for more targeted and effective therapies. This could lead to significant advancements in treatment options, offering new hope for patients battling this aggressive cancer.
Who Is on the Research Team?
Daniel J Renouf, MD
Principal Investigator
BC Cancer
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo fresh tumour biopsy and collection of baseline blood samples for comprehensive molecular characterization
Treatment
Participants receive first-line systemic chemotherapy with FOLFIRINOX or GP-based regimens, with serial collection of plasma and serum samples every 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, with CT scans every 8 weeks and optional second tumour biopsy at disease progression
What Are the Treatments Tested in This Trial?
Interventions
- Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes
Find a Clinic Near You
Who Is Running the Clinical Trial?
British Columbia Cancer Agency
Lead Sponsor
Terry Fox Research Institute
Collaborator
BC Cancer Foundation
Collaborator
Pancreas Centre BC
Collaborator
American Society of Clinical Oncology
Collaborator